Adalvo Partners With SK Pharma to Create Arphio, a New Business Entity Dedicated Solely to Orphan and Rare Disease Medicines
Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM (www.arphio.com), a venture initiated in close collaboration with SK Pharma.
Together with our new partner, we are developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs.
ArphioTM will operate as an independent entity, focusing on rare disease detection, market access and supply of orphan drugs, targeting the EU and ROW regions. ArphioTM has a unique understanding on orphan products and their epidemiology data and unique characteristics. The aim of this venture is to expand access to vital treatments and continue to develop technological capabilities and expertise, while maintaining a patient-centric approach with the possibility of relying on state-of-the art novel technology including worldwide data, artificial intelligence, and machine learning.
Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms in various parts of the globe. The company is focused on rare disease detection, market access and the supply of orphan drugs internationally.
Arphio is powered by DrugsIntel (DI), a data science powerhouse focusing on the aggregation, unleashing, processing, unification and deployment of pharmaceutical data covering over 75 countries, and over 6,000 sources. This intelligence tools ensure the successful launch of orphan drugs in the market of operation, based on DI’s unique methodology of these Six factors and Pillars.
This stand-alone market player will cover all services and functions ranging from medical, market access, regulatory, direct sales, and marketing activities. ArphioTM proudly boasts of strictly following ethics, compliance, accessibility, and corporate governance.
There are over 300 million people living with one or more of over 7,000 identified rare diseases around the world, each supported by family, friends, and caregivers. Currently, only about 5% of orphan disorders can be managed with an approved treatment. It is estimated that it takes about seven years and visits to 10 different doctors for a patient to receive a proper diagnostic of an orphan condition. At ArphioTM, fueled by our passion to improve people’s lives, we will apply innovative technologies to provide effective treatments for people with orphan diseases.
Anil Okay, General Manager at Adalvo comments: “We are thrilled to be partnering with SK Pharma on this exciting new journey. We welcome this opportunity to work in the domain of Orphan drugs, and we are eager to make a valuable contribution to patients across the globe who are living with Rare diseases”.
Dr. Shlomo Sadoun, CEO at SK Pharma comments: “I’m captivated to have Adalvo as our partner with the important endeavor of helping neglected orphan patients and their caregivers with their unmet medical needs. I’m bullish on the synergistical power that could outcome from this collaboration for the benefit of rare disease patients".
https://www.linkedin.com/company/arphiopr/about/
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 70 countries and for over 90 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners. With headquarters in Malta, the company has additional offices in more than 15 countries such as Switzerland, UK, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Portugal, Czech Republic, and India. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners. The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
Visit: www.adalvo.com
About SK Pharma
SK-Pharma is a global pharmaceutical company focusing on making drugs accessible to patients in needs. The vison of the company lay in utilizing cutting edge technologies to support smart business decisions that will lead to better healthcare solutions. Taking patient centric approach, the company holistically follow the patient’s journey and understand better their unmet needs. Mimicking the patient journey allow us to come with viable solutions that change the patient treatment paradigm and make it more suitable to their lifestyle and their unique needs. The group is divided to three divisions: First to launch and the introduction of complex hybrid generic products. The second division is focusing on providing technological solutions to enhance smart business decisions. The third division is specialized in orphan drugs market access and distribution worldwide. Visit: https://sk-pharma.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005409/en/
Contact information
Gabrielle Cassar
Gabrielle.Cassar@adalvo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Announces Senior Leadership Changes to Accelerate Growth and Drive Win Now Action Plan5.5.2025 23:15:00 EEST | Press release
NIKE, Inc. (NYSE:NKE) announced a series of strategic changes to its Senior Leadership Team (SLT), elevating experienced leaders to accelerate progress against its Win Now action plan to position the company for future growth. Elliott Hill, President and CEO, NIKE, Inc. and Heidi O’Neill, President of Consumer, Product, and Brand, have decided the Consumer, Product, and Brand leadership will now be divided into three distinct areas: Consumer and Sport, Marketing, and Product Creation, inclusive of Innovation and Design. These roles will now report directly to Hill. As a result of these changes O’Neill has decided to retire from Nike after 26 years. She will continue to serve in an advisory capacity until September 2025. “For nearly three decades, Heidi has been a true champion for Nike, for sport and for athletes across the globe. Her vision and dedication over the years have left an indelible mark on Nike and created an impact on the world of sport,” said Hill. “Among Heidi’s many suc
LR Health & Beauty Once Again Demonstrates Its Expertise in Aloe Vera5.5.2025 17:24:00 EEST | Press release
LR Health & Beauty has been synonymous with the best Aloe Vera quality on the market for over 20 years, and continuously invests in new product innovations to take full advantage of the plant's range of beneficial properties. The majority of the over 60 products are developed and produced directly at the company headquarters in Ahlen. LR has now made a decisive breakthrough in skin care cosmetics with its unique combination of pure Aloe Vera leaf gel and fermented Aloe Vera. The care products with the highest Aloe Vera content therefore not only work in the upper and middle layers of the skin, but also unleash the full potential of Aloe Vera in the deeper layers. The effectiveness of this LR Aloe Via Magic Power Duo has been confirmed by the dermatological institute, Dermatest. All the products tested based on a combination of Aloe Vera Gel and fermented Aloe were awarded the 5-star "very good" seal by Dermatest. The test results* show increased moisture retention (up to 176%), improve
MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets5.5.2025 17:09:00 EEST | Press release
MultiBank Group, the world’s largest financial derivatives institution based in Dubai has signed a historic $3 billion tokenization agreement with MAG, the leading real estate developer in the UAE, and Mavryk, a leading blockchain innovator — marking the largest real-world asset (RWA) tokenization initiative globally to date. The initiative highlights the imminent launch of $MBG, the utility token at the core of MultiBank’s next-generation digital finance ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505317631/en/ MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets The partnership will bring MAG’s high-value real estate developments — The Ritz-Carlton Residences, Dubai, Creekside, which is part of the Keturah Resort, and Keturah Reserve — onto the blockchain, making them available to global investors via MultiBank.io’s fully regulated RWA marketplace. Once launched, h
3Degrees Grows Carbon Asset Development Capabilities in Singapore5.5.2025 16:30:00 EEST | Press release
3Degrees, a leading global climate solutions provider, announced today that it will be expanding its carbon asset development capabilities in Singapore. The move will see the company developing a pipeline of projects that are aligned with Article 6 of the Paris Agreement across Southeast Asia and beyond, supporting the region’s growing demand for credible, science-based climate action. The company brings nearly two decades of market experience and technical expertise to the region and is well-positioned to help operationalize Article 6 through high-integrity, scalable project development—enabling both environmental impact and market confidence. This expansion will be supported by the Singapore Economic Development Board (EDB)’s Carbon Project Development grant. The grant aims to support early-stage carbon project development and financing activities for Article 6 carbon credit projects. The initiative reinforces Singapore’s position as a global hub for high-integrity climate solutions
Sitetracker Launches Enhanced O&M Tools to Drive Efficiency Across the Asset Lifecycle5.5.2025 16:00:00 EEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management, today announced significant enhancements to its Operations and Maintenance (O&M) solution. These advancements reinforce Sitetracker's position as the leading end-to-end platform built to help asset owners and contractors plan, build, operate, and maintain critical infrastructure at scale. As infrastructure networks grow more distributed and complex—driven by the accelerating energy transition, AI’s demand on energy and digital infrastructure, and global connectivity—operations and maintenance teams are under increasing pressure. Assets are often deployed in remote locations, teams are expected to do more with fewer resources, and the margin for error has never been slimmer. Success now depends on having intelligent, scalable tools that enable safe, efficient, and proactive asset management at every stage. “Operations and maintenance are no longer back-office functions—they're front and center in ensuring ROI and rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom